Drug Trial Radar · NCT03041259
Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction
Last checked: Nov 19, 2026Latest source record: Aug 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
320
Planned (sponsor's estimate)
Start
Jan 2020
Primary completion
Jan 2022
Study completion Jul 2022
Sponsor
- Lead sponsor
- Reven Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients with Rutherford Class 4, 5 and 6 Disease
Conditions
- Critical Limb Ischemia
- Peripheral Arterial Disease
Interventions
Rejuveinix Low DoseDrug
A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
Rejuveinix High DoseDrug
A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients with Treatment-related Major Adverse Events as Defined by Re-intervention of the Target Vessel(s), Limb Amputation or Endovascular-related Death.Time frame: 84 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.